Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cymabay Therapeutics (CBAY)

Cymabay Therapeutics (CBAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Trimble, CymaBay Therapy rise; Big Lots, Monday.com fall, Monday, 2/12/2024

Stocks that traded heavily or had substantial price changes on Monday: Trimble, CymaBay Therapy rise; Big Lots, Monday

BIG : 0.4968 (+9.11%)
TRMB : 61.21 (+1.17%)
BBGI : 12.54 (-0.32%)
FANG : 175.81 (-0.54%)
CBAY : 32.48 (+0.03%)
Why CymaBay Therapeutics Stock Rocketed Nearly 8% Higher Today

It became increasingly likely that seladelpar will ultimately gain regulatory approval.

CBAY : 32.48 (+0.03%)
Why CymaBay Therapeutics Stock Is Sinking This Week

The stock has given up some of its gains but remains up more than 130% year to date.

CBAY : 32.48 (+0.03%)
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday

The company is about to reap more money than previously expected from a new capital-raising effort.

CBAY : 32.48 (+0.03%)
Why CymaBay Therapeutics Stock Popped Again Today

Days after it reported highly encouraging news from a clinical trial, the company announced a new round of capital-raising.

CBAY : 32.48 (+0.03%)
Why CymaBay Therapeutics Stock Is Jumping Today

The momentum continues after CymaBay reported great clinical results on Thursday.

ICPT : 19.00 (+0.21%)
CBAY : 32.48 (+0.03%)
CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase

/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...

CBAY : 32.48 (+0.03%)
Why Shares of CymaBay Therapeutics Are Soaring Friday

A competitor's drug had a so-so phase 3 trial, lifting the possibilities for CymaBay's lead therapy.

RJF : 144.29 (-2.65%)
CBAY : 32.48 (+0.03%)
CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels

/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other...

CBAY : 32.48 (+0.03%)
CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congressâ„¢ 2023

/PRNewswire/ -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other...

CBAY : 32.48 (+0.03%)

Barchart Exclusives

3 High-Yield Dividend Stocks Ready to Surge in 2025
These three companies pay above-average dividends, and their stocks still look cheap. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar